Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
This report covers acute myeloid leukemia (AML) results from a multicenter, prospective observational study of AML, myelodysplastic syndromes, and chronic myelomonocytic leukemia in Japan. From August 2011 to January 2016, 3728 AML patients were registered. Among them, 42% were younger than 65, and the male-to-female ratio was 1.57:1. With a median follow-up time of 1807 days (95% confidence interval [CI]: 1732-1844 days), the estimated 5-year overall survival (OS) rate in AML patients (n = 3707) was 31.1% (95% CI: 29.5-32.8%). Trial-enrolled patients had a 1.7-fold higher OS rate than non-enrolled patients (5-year OS, 58....
Source: International Journal of Hematology - November 28, 2023 Category: Hematology Authors: Kensuke Usuki Shigeki Ohtake Sumihisa Honda Mitsuhiro Matsuda Atsushi Wakita Yuichiro Nawa Ken Takase Akio Maeda Nobuo Sezaki Hisayuki Yokoyama Satoru Takada Daiki Hirano Tatsuki Tomikawa Masahiko Sumi Shingo Yano Hiroshi Handa Shuichi Ota Hiroyuki Fujita Source Type: research

Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
This report covers acute myeloid leukemia (AML) results from a multicenter, prospective observational study of AML, myelodysplastic syndromes, and chronic myelomonocytic leukemia in Japan. From August 2011 to January 2016, 3728 AML patients were registered. Among them, 42% were younger than 65, and the male-to-female ratio was 1.57:1. With a median follow-up time of 1807 days (95% confidence interval [CI]: 1732-1844 days), the estimated 5-year overall survival (OS) rate in AML patients (n = 3707) was 31.1% (95% CI: 29.5-32.8%). Trial-enrolled patients had a 1.7-fold higher OS rate than non-enrolled patients (5-year OS, 58....
Source: International Journal of Hematology - November 28, 2023 Category: Hematology Authors: Kensuke Usuki Shigeki Ohtake Sumihisa Honda Mitsuhiro Matsuda Atsushi Wakita Yuichiro Nawa Ken Takase Akio Maeda Nobuo Sezaki Hisayuki Yokoyama Satoru Takada Daiki Hirano Tatsuki Tomikawa Masahiko Sumi Shingo Yano Hiroshi Handa Shuichi Ota Hiroyuki Fujita Source Type: research

Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
This report covers acute myeloid leukemia (AML) results from a multicenter, prospective observational study of AML, myelodysplastic syndromes, and chronic myelomonocytic leukemia in Japan. From August 2011 to January 2016, 3728 AML patients were registered. Among them, 42% were younger than 65, and the male-to-female ratio was 1.57:1. With a median follow-up time of 1807 days (95% confidence interval [CI]: 1732-1844 days), the estimated 5-year overall survival (OS) rate in AML patients (n = 3707) was 31.1% (95% CI: 29.5-32.8%). Trial-enrolled patients had a 1.7-fold higher OS rate than non-enrolled patients (5-year OS, 58....
Source: International Journal of Hematology - November 28, 2023 Category: Hematology Authors: Kensuke Usuki Shigeki Ohtake Sumihisa Honda Mitsuhiro Matsuda Atsushi Wakita Yuichiro Nawa Ken Takase Akio Maeda Nobuo Sezaki Hisayuki Yokoyama Satoru Takada Daiki Hirano Tatsuki Tomikawa Masahiko Sumi Shingo Yano Hiroshi Handa Shuichi Ota Hiroyuki Fujita Source Type: research

Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
This report covers acute myeloid leukemia (AML) results from a multicenter, prospective observational study of AML, myelodysplastic syndromes, and chronic myelomonocytic leukemia in Japan. From August 2011 to January 2016, 3728 AML patients were registered. Among them, 42% were younger than 65, and the male-to-female ratio was 1.57:1. With a median follow-up time of 1807 days (95% confidence interval [CI]: 1732-1844 days), the estimated 5-year overall survival (OS) rate in AML patients (n = 3707) was 31.1% (95% CI: 29.5-32.8%). Trial-enrolled patients had a 1.7-fold higher OS rate than non-enrolled patients (5-year OS, 58....
Source: International Journal of Hematology - November 28, 2023 Category: Hematology Authors: Kensuke Usuki Shigeki Ohtake Sumihisa Honda Mitsuhiro Matsuda Atsushi Wakita Yuichiro Nawa Ken Takase Akio Maeda Nobuo Sezaki Hisayuki Yokoyama Satoru Takada Daiki Hirano Tatsuki Tomikawa Masahiko Sumi Shingo Yano Hiroshi Handa Shuichi Ota Hiroyuki Fujita Source Type: research

Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11)
This report covers acute myeloid leukemia (AML) results from a multicenter, prospective observational study of AML, myelodysplastic syndromes, and chronic myelomonocytic leukemia in Japan. From August 2011 to January 2016, 3728 AML patients were registered. Among them, 42% were younger than 65, and the male-to-female ratio was 1.57:1. With a median follow-up time of 1807 days (95% confidence interval [CI]: 1732-1844 days), the estimated 5-year overall survival (OS) rate in AML patients (n = 3707) was 31.1% (95% CI: 29.5-32.8%). Trial-enrolled patients had a 1.7-fold higher OS rate than non-enrolled patients (5-year OS, 58....
Source: International Journal of Hematology - November 28, 2023 Category: Hematology Authors: Kensuke Usuki Shigeki Ohtake Sumihisa Honda Mitsuhiro Matsuda Atsushi Wakita Yuichiro Nawa Ken Takase Akio Maeda Nobuo Sezaki Hisayuki Yokoyama Satoru Takada Daiki Hirano Tatsuki Tomikawa Masahiko Sumi Shingo Yano Hiroshi Handa Shuichi Ota Hiroyuki Fujita Source Type: research

Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia
Int J Hematol. 2023 Nov 27. doi: 10.1007/s12185-023-03678-9. Online ahead of print.ABSTRACTMyeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) is a rare leukemia subtype that possibly originates from precursor NK cells. The disease has a poor prognosis, and information on its treatment is lacking. We herein report the first case of a 46-year-old woman with MNKPL who was refractory to two lines of acute myeloid leukemia (AML)-type intensive chemotherapy but was successfully treated with venetoclax and azacytidine (VEN/AZA). She was diagnosed with MNKPL based on the conformations of immature lymphoblastoid morp...
Source: International Journal of Hematology - November 27, 2023 Category: Hematology Authors: Ichiro Shiomi Soichiro Nakako Takahiko Nakane Yumi Ogawa Taku Araki Yotaro Fujitani Ryosuke Yamamura Masayuki Hino Hirohisa Nakamae Source Type: research

Effectiveness of venetoclax and azacytidine against myeloid/natural killer cell precursor acute leukemia
Int J Hematol. 2023 Nov 27. doi: 10.1007/s12185-023-03678-9. Online ahead of print.ABSTRACTMyeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) is a rare leukemia subtype that possibly originates from precursor NK cells. The disease has a poor prognosis, and information on its treatment is lacking. We herein report the first case of a 46-year-old woman with MNKPL who was refractory to two lines of acute myeloid leukemia (AML)-type intensive chemotherapy but was successfully treated with venetoclax and azacytidine (VEN/AZA). She was diagnosed with MNKPL based on the conformations of immature lymphoblastoid morp...
Source: International Journal of Hematology - November 27, 2023 Category: Hematology Authors: Ichiro Shiomi Soichiro Nakako Takahiko Nakane Yumi Ogawa Taku Araki Yotaro Fujitani Ryosuke Yamamura Masayuki Hino Hirohisa Nakamae Source Type: research

Histopathological maturation in juvenile xanthogranuloma: a blueberry muffin infant mimicking aleukemic leukemia cutis
In conclusion, distinguishing non-typical JXG from aleukemic leukemia cutis is challenging. This case highlights the importance of multiple biopsies and the potential for histopathological maturation.PMID:37989992 | DOI:10.1007/s12185-023-03675-y (Source: International Journal of Hematology)
Source: International Journal of Hematology - November 22, 2023 Category: Hematology Authors: Yuta Sakai Yasuhiro Ikawa Mika Takenaka Kazuhiro Noguchi Toshihiro Fujiki Hiroko Ikeda Taizo Wada Source Type: research

Histopathological maturation in juvenile xanthogranuloma: a blueberry muffin infant mimicking aleukemic leukemia cutis
In conclusion, distinguishing non-typical JXG from aleukemic leukemia cutis is challenging. This case highlights the importance of multiple biopsies and the potential for histopathological maturation.PMID:37989992 | DOI:10.1007/s12185-023-03675-y (Source: International Journal of Hematology)
Source: International Journal of Hematology - November 22, 2023 Category: Hematology Authors: Yuta Sakai Yasuhiro Ikawa Mika Takenaka Kazuhiro Noguchi Toshihiro Fujiki Hiroko Ikeda Taizo Wada Source Type: research

Histopathological maturation in juvenile xanthogranuloma: a blueberry muffin infant mimicking aleukemic leukemia cutis
In conclusion, distinguishing non-typical JXG from aleukemic leukemia cutis is challenging. This case highlights the importance of multiple biopsies and the potential for histopathological maturation.PMID:37989992 | DOI:10.1007/s12185-023-03675-y (Source: International Journal of Hematology)
Source: International Journal of Hematology - November 22, 2023 Category: Hematology Authors: Yuta Sakai Yasuhiro Ikawa Mika Takenaka Kazuhiro Noguchi Toshihiro Fujiki Hiroko Ikeda Taizo Wada Source Type: research

Histopathological maturation in juvenile xanthogranuloma: a blueberry muffin infant mimicking aleukemic leukemia cutis
In conclusion, distinguishing non-typical JXG from aleukemic leukemia cutis is challenging. This case highlights the importance of multiple biopsies and the potential for histopathological maturation.PMID:37989992 | DOI:10.1007/s12185-023-03675-y (Source: International Journal of Hematology)
Source: International Journal of Hematology - November 22, 2023 Category: Hematology Authors: Yuta Sakai Yasuhiro Ikawa Mika Takenaka Kazuhiro Noguchi Toshihiro Fujiki Hiroko Ikeda Taizo Wada Source Type: research

Clonal hematopoiesis of a novel dic(18;20) clone following allogeneic hematopoietic stem cell transplantation
Int J Hematol. 2023 Nov 18. doi: 10.1007/s12185-023-03673-0. Online ahead of print.ABSTRACTA 55-year-old man in first complete remission of acute myeloid leukemia with a normal karyotype underwent allogeneic hematopoietic stem cell transplantation from a human-leukocyte-antigen-matched sibling. Bone marrow examination on day 28 confirmed complete remission, but G-banding analysis revealed a novel chromosomal abnormality, including dic(18;20)(p11.2;q11.2). The patient developed moderate chronic graft-versus-host disease on day 174, and the abnormal clones identified by dic(18;20) significantly increased after that point. Ch...
Source: International Journal of Hematology - November 18, 2023 Category: Hematology Authors: Makoto Ito Nobuaki Fukushima Tomoki Fujii Masaya Numata Shiori Morikawa Yuma Kawamura Miyo Goto Akio Kohno Nobuhiko Imahashi Takahiko Yasuda Masashi Sanada Yuichi Ishikawa Hitoshi Kiyoi Kazutaka Ozeki Source Type: research

Clonal hematopoiesis of a novel dic(18;20) clone following allogeneic hematopoietic stem cell transplantation
Int J Hematol. 2023 Nov 18. doi: 10.1007/s12185-023-03673-0. Online ahead of print.ABSTRACTA 55-year-old man in first complete remission of acute myeloid leukemia with a normal karyotype underwent allogeneic hematopoietic stem cell transplantation from a human-leukocyte-antigen-matched sibling. Bone marrow examination on day 28 confirmed complete remission, but G-banding analysis revealed a novel chromosomal abnormality, including dic(18;20)(p11.2;q11.2). The patient developed moderate chronic graft-versus-host disease on day 174, and the abnormal clones identified by dic(18;20) significantly increased after that point. Ch...
Source: International Journal of Hematology - November 18, 2023 Category: Hematology Authors: Makoto Ito Nobuaki Fukushima Tomoki Fujii Masaya Numata Shiori Morikawa Yuma Kawamura Miyo Goto Akio Kohno Nobuhiko Imahashi Takahiko Yasuda Masashi Sanada Yuichi Ishikawa Hitoshi Kiyoi Kazutaka Ozeki Source Type: research

Clonal hematopoiesis of a novel dic(18;20) clone following allogeneic hematopoietic stem cell transplantation
Int J Hematol. 2023 Nov 18. doi: 10.1007/s12185-023-03673-0. Online ahead of print.ABSTRACTA 55-year-old man in first complete remission of acute myeloid leukemia with a normal karyotype underwent allogeneic hematopoietic stem cell transplantation from a human-leukocyte-antigen-matched sibling. Bone marrow examination on day 28 confirmed complete remission, but G-banding analysis revealed a novel chromosomal abnormality, including dic(18;20)(p11.2;q11.2). The patient developed moderate chronic graft-versus-host disease on day 174, and the abnormal clones identified by dic(18;20) significantly increased after that point. Ch...
Source: International Journal of Hematology - November 18, 2023 Category: Hematology Authors: Makoto Ito Nobuaki Fukushima Tomoki Fujii Masaya Numata Shiori Morikawa Yuma Kawamura Miyo Goto Akio Kohno Nobuhiko Imahashi Takahiko Yasuda Masashi Sanada Yuichi Ishikawa Hitoshi Kiyoi Kazutaka Ozeki Source Type: research

Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition
Int J Hematol. 2023 Nov 13. doi: 10.1007/s12185-023-03672-1. Online ahead of print.ABSTRACTPrimary immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia due to accelerated platelet destruction and impaired platelet production. Diagnosis of ITP is still challenging because ITP has been diagnosed by exclusion. Exclusion of thrombocytopenia due to bone marrow failure is especially important in Japan because of high prevalence of aplastic anemia compared to Western countries. Hence, we propose a new diagnostic criteria involving the measurement of plasma thrombopoietin (TPO) levels ...
Source: International Journal of Hematology - November 13, 2023 Category: Hematology Authors: Hirokazu Kashiwagi Masataka Kuwana Mitsuru Murata Naoki Shimada Toshiro Takafuta Jun Yamanouchi Hisashi Kato Takaaki Hato Yoshiaki Tomiyama Committee for Reference Guide for diagnosis of adult ITP Research Team for Coagulopathy and Other Intractable Disea Source Type: research